Monoclonal Antibody Conjugate to Target GPC1 for Oncology is under clinical development by GlyTherix and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Monoclonal Antibody Conjugate to Target GPC1 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monoclonal Antibody Conjugate to Target GPC1 for Oncology overview
Monoclonal antibody conjugate is under development for the treatment of metastatic prostate cancer, metastatic pancreatic cancer, metastatic urothelial cancer, bladder cancer, ureter cancer, urethral cancer, glioblastoma, breast cancer, ovarian cancer and esophageal cancer. It is administered through intravenous route. The drug candidate constitutes of miltuximab conjugated with lutetium-177 (177Lu) acts through cells expressing glypican 1 (GPC1).
GlyTherix, is a biotech company that specialises in immuno oncology therapeutics for solid tumors, targeted treatment of prostate, bladder and pancreas cancers. The company is headquartered in Macquarie Park, New South Wales, Australia.
For a complete picture of Monoclonal Antibody Conjugate to Target GPC1 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.